A New Era for Molecular Cloning and Biologics Design
Revvity, Inc. (NYSE: RVTY) has officially introduced Signals BioDesign™, a next-generation cloud-native molecular cloning solution designed to streamline biologics research workflows. Developed under the Revvity Signals Software division, this platform aims to support biotech and pharmaceutical R&D teams by simplifying complex cloning processes while enabling scalable and collaborative innovation.
Built to overcome the limitations of traditional desktop-based tools, Signals BioDesign provides a modern, unified environment where researchers can design, manage, and execute cloning strategies more efficiently. The solution reflects the growing need for integrated digital ecosystems in life sciences research.
Comprehensive Cloning Workflows in One Platform
Signals BioDesign delivers a complete set of molecular cloning capabilities within a single application. It supports widely used methodologies such as Golden Gate assembly, Gibson assembly, and restriction/ligation workflows, along with primer design, Sanger sequencing analysis, and protein translation tools.
By consolidating these functionalities into one platform, researchers can eliminate the need for multiple disconnected tools, reducing errors and improving workflow efficiency. This unified approach enables faster design cycles and enhances reproducibility across experiments.
High-Throughput Design and Scalable Collaboration
One of the key strengths of Signals BioDesign is its ability to support high-throughput construct design, allowing teams to generate and manage up to 1,000 constructs simultaneously. This capability is particularly valuable for large-scale biologics development projects, where speed and scalability are critical.
The platform’s cloud-native architecture enables real-time collaboration between distributed teams, ensuring that data is instantly accessible and consistently updated. Centralized sequence libraries, duplicate detection, and advanced construct management tools further enhance productivity while minimizing redundancy and data silos.
Cloud-Native Infrastructure and AI-Ready Ecosystem
Signals BioDesign is fully integrated within the Signals One™ platform, creating a connected biologics research ecosystem that links design, execution, and data capture. This integration allows seamless interaction with bioregistration systems and multi-modal experimental data, supporting a more holistic approach to research workflows.
The platform’s cloud-native SaaS model removes the operational burden associated with desktop software, including installation, updates, and compliance risks. Additionally, its AI-ready data infrastructure positions organizations to leverage machine learning for sequence optimization and predictive design in the future.
Accelerating the Development of Next-Generation Therapies
According to Revvity, the Signals BioDesign solution addresses a critical need for molecular biology teams working on advanced therapeutics, including antibody-based treatments, cell therapies, and gene therapies.
By enabling centralized construct management and enterprise-level collaboration without unnecessary complexity, the platform helps accelerate development timelines and supports more efficient translation from research to clinical applications.
Industry Impact and Upcoming Launch Event
Revvity will officially showcase Signals BioDesign at the Bio-IT World Conference & Expo, taking place from May 19–21 in Boston, Massachusetts. This event will provide researchers and industry professionals with an opportunity to explore the platform’s capabilities and its role in advancing biologics innovation.
With its focus on integration, scalability, and digital transformation, Signals BioDesign represents a significant step forward in modernizing molecular cloning workflows and supporting the future of precision medicine.